Adding tumor-bed biopsy to trimodality imaging after neoadjuvant chemotherapy did not reliably predict pathological complete ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...

(Reuters) -Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen (AMGN) stock in focus as its antibody drug Tepezza becomes U.K.'s first medicine for adults with moderate to severe ...

Amgen Inc. outperformed Wall Street’s quarterly profit estimates as it moves forward with plans to crack the ...

It's also a great place to start if you're looking for dividend stocks, as nearly every stock on the Dow Jones Industrial ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...